Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia

Ahmed Alghamdi; Bander Balkhi; Abdulaziz Altowaijri; Nasser Al-shehri; Lewis Ralph; Emily-Ruth Marriott; Michael Urbich; Fawaz Aljanad; Rima Aziziyeh

doi:10.1007/s41669-021-00300-8

Back

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia

Journal article

Open access

Peer reviewed

Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia

Ahmed Alghamdi, Bander Balkhi, Abdulaziz Altowaijri, Nasser Al-shehri, Lewis Ralph, Emily-Ruth Marriott, Michael Urbich, Fawaz Aljanad and Rima Aziziyeh

PharmacoEconomics - open, Vol.6(2), pp.277-291

01/03/2022

DOI: https://doi.org/10.1007/s41669-021-00300-8

PMID: 34582002

Abstract

Original

Files and links (1)

url

https://doi.org/10.1007/s41669-021-00300-8View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia
Creators - without role: Ahmed Alghamdi - King Saud University
Bander Balkhi - King Saud University
Abdulaziz Altowaijri - Prince Sultan University
Nasser Al-shehri - Riyadh, Saudi Arabia
Lewis Ralph - BresMed
Emily-Ruth Marriott - BresMed
Michael Urbich - Amgen
Fawaz Aljanad - Amgen Inc, Riyadh, RYD Saudi Arabia
Rima Aziziyeh - Amgen
Publication Details: PharmacoEconomics - open, Vol.6(2), pp.277-291
Publisher: Springer International Publishing
Identifiers: 9947542908331
Academic Unit: King Saud University; King Abdulaziz University
Language: English
Resource Type: Journal article